Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Steven D NathanShalika B KatugahaAdam CochraneAnne Whitney BrownSteven D NathanOksana A ShlobinKareem AhmadLauren MarinakJessica ChunMargaret FregosoShashank DesaiChristopher KingPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
Letermovir was well tolerated with only minor side effects reported; however, the rate of development of CMV DNAemia on prophylaxis was considerable. Further study of the dosing and efficacy of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients is warranted.